Literature DB >> 1449241

The identification of presymptomatic parkinsonism: clinical and [18F]dopa positron emission tomography studies in an Irish kindred.

G V Sawle1, S J Wroe, A J Lees, D J Brooks, R S Frackowiak.   

Abstract

An Irish kindred is described in which 5 of 10 siblings in the fourth or fifth decade of life developed an akinetic-rigid syndrome clinically indistinguishable from idiopathic Lewy body Parkinson's disease. Four of these patients were scanned by positron emission tomography (PET) with [18F]dopa after clinical diagnosis and in all, a profound impairment of tracer uptake into the striatum was recorded. The fifth patient was initially scanned at a time when he was asymptomatic and normal by clinical examination. His scan showed impaired tracer uptake, indicating a subclinical defect in the presynaptic nigrostriatal system. Within months of his scan, he too developed subtle symptoms and signs of parkinsonism although there was little further clinical progression or change in his PET scan over the following year. A clinically normal sibling was also scanned and found to have subclinical impairment of [18F]dopa uptake in the putamen. The 19-year-old daughter of an affected sibling had a mild postural tremor but no other symptoms or signs. The [18F]dopa uptake in her putamen fell at the borderline between normal and parkinsonian values. This study confirms that PET can identify preclinical parkinsonism in at-risk subjects. The finding of abnormalities in several clinically unaffected family members suggests that family studies based on clinical assessment alone may miss a significant number of subclinically affected individuals, leading to an underestimate of any genetic component to Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1449241     DOI: 10.1002/ana.410320503

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  12 in total

1.  Neuropsychological abnormalities in first degree relatives of patients with familial Parkinson's disease.

Authors:  K Dujardin; A Duhamel; E Becquet; C Grunberg; L Defebvre; A Destee
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography.

Authors:  Z Walker; D C Costa; A G Janssen; R W Walker; G Livingstone; C L Katona
Journal:  Eur J Nucl Med       Date:  1997-06

3.  Genes and parkinsonism.

Authors:  N Wood
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

4.  PET radiopharmaceuticals for probing enzymes in the brain.

Authors:  Jason P Holland; Paul Cumming; Neil Vasdev
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

Review 5.  Early detection of Parkinson's disease. Implications for treatment.

Authors:  R Di Paola; R J Uitti
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

Review 6.  Imaging the head: functional imaging.

Authors:  G V Sawle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

Review 7.  Nuclear and mitochondrial genetics in Parkinson's disease.

Authors:  A H Schapira
Journal:  J Med Genet       Date:  1995-06       Impact factor: 6.318

8.  Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease.

Authors:  V Planté-Bordeneuve; M B Davis; D M Maraganore; C D Marsden; A E Harding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

9.  Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease.

Authors:  K Ito; P K Morrish; J S Rakshi; T Uema; J Ashburner; D L Bailey; K J Friston; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-06       Impact factor: 10.154

10.  Reduced uptake of [¹⁸F]FDOPA PET in asymptomatic welders with occupational manganese exposure.

Authors:  S R Criswell; J S Perlmutter; T O Videen; S M Moerlein; H P Flores; A M Birke; B A Racette
Journal:  Neurology       Date:  2011-04-06       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.